48,736 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

Key Points

• The Virginia Retirement Systems acquired 48,736 shares of Supernus Pharmaceuticals, valued at approximately $1.54 million, representing 0.09% ownership as of the latest SEC filing.
• Supernus Pharmaceuticals shares opened at $50.67, with a 52-week range between $29.16 and $52.15, and a market capitalization of $2.84 billion.
• Analysts have set an average target price of $64.00, with upgrades from several brokerages, including Piper Sandler, which raised their target from $40.00 to $65.00.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 48,736 shares of the specialty pharmaceutical company's stock, valued at approximately $1,536,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.09% of Supernus Pharmaceuticals as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its stake in Supernus Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after purchasing an additional 9,590 shares during the period. Robeco Institutional Asset Management B.V. bought a new position in Supernus Pharmaceuticals in the 1st quarter worth $267,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Supernus Pharmaceuticals in the 1st quarter worth $2,148,000. Meritage Portfolio Management grew its position in Supernus Pharmaceuticals by 2.7% in the 2nd quarter. Meritage Portfolio Management now owns 60,398 shares of the specialty pharmaceutical company's stock worth $1,904,000 after purchasing an additional 1,595 shares during the last quarter. Finally, QRG Capital Management Inc. grew its position in Supernus Pharmaceuticals by 7.4% in the 2nd quarter. QRG Capital Management Inc. now owns 18,892 shares of the specialty pharmaceutical company's stock worth $595,000 after purchasing an additional 1,309 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $50.67 on Thursday. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $52.15. The company has a market capitalization of $2.84 billion, a PE ratio of 44.06 and a beta of 0.78. The company has a 50 day moving average price of $46.47 and a two-hundred day moving average price of $37.63.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SUPN. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $40.00 to $65.00 in a research report on Thursday, October 9th. Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 30th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Weiss Ratings reissued a "hold (c)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $64.00.

Insider Activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 140,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total value of $5,882,800.00. Following the completion of the transaction, the chief executive officer directly owned 1,030,183 shares of the company's stock, valued at approximately $43,288,289.66. This represents a 11.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total value of $315,132.82. Following the transaction, the director owned 46,307 shares of the company's stock, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 362,741 shares of company stock worth $16,390,592 over the last ninety days. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.